50 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Biogen Up on New Data on Alzheimer's Candidate Aducanumab http://www.zacks.com/stock/news/657638/biogen-up-on-new-data-on-alzheimers-candidate-aducanumab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-657638 Dec 06, 2019 - Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.
Biotech ETFs Hit New Highs on Deal Activities http://www.zacks.com/stock/news/663878/biotech-etfs-hit-new-highs-on-deal-activities?cid=CS-ZC-FT-etf_news_and_commentary-663878 Dec 10, 2019 - Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar http://www.zacks.com/stock/news/665488/biotech-stock-roundup-ash-data-in-focus-amgen-gets-fda-nod-to-remicade-biosimilar?cid=CS-ZC-FT-analyst_blog|stock_roundup-665488 Dec 11, 2019 - The biotech sector witnesses pipeline updates from the annual ASH meet.
AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU http://www.zacks.com/stock/news/678331/abbvies-jak-inhibitor-rinvoq-receives-approval-for-ra-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-678331 Dec 19, 2019 - AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.
Merck's Keytruda Misses One of Two Goals in Lung Cancer Study http://www.zacks.com/stock/news/706462/mercks-keytruda-misses-one-of-two-goals-in-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-706462 Jan 07, 2020 - Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints. It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - January 13, 2020 http://www.zacks.com/stock/news/715571/know-these-3-facts-to-avoid-paying-half-your-retirement-income-to-the-irs-january-13-2020?cid=CS-ZC-FT-retirement_ideas|required_minimum_distribution-715571 Jan 13, 2020 - Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.
Biogen Acquires Early-Stage CNS Drug From Pfizer for $75M http://www.zacks.com/stock/news/717331/biogen-acquires-early-stage-cns-drug-from-pfizer-for-%2475m?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-717331 Jan 14, 2020 - Biogen (BIIB) signs deals with Pfizer to acquire rights to a CNS candidate and develop it as potential therapy to treat certain symptoms/disorders related to Alzheimer's disease and Parkinson's disease.
5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates http://www.zacks.com/stock/news/729100/5-big-drug-biotech-stocks-set-to-trump-q4-earnings-estimates?cid=CS-ZC-FT-earnings_esp-729100 Jan 22, 2020 - Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
What Lies Ahead for Healthcare ETFs in Q4 Earnings? http://www.zacks.com/stock/news/731805/what-lies-ahead-for-healthcare-etfs-in-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-731805 Jan 24, 2020 - With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings? http://www.zacks.com/stock/news/731666/will-pfizers-pfe-biopharma-unit-boost-its-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-731666 Jan 24, 2020 - Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.

Pages: 12345

<<<Page 4